GlucoTrack Other Stockholder Equity from 2010 to 2025

GCTK Stock  USD 0.23  0.01  4.17%   
GlucoTrack Other Stockholder Equity yearly trend continues to be quite stable with very little volatility. Other Stockholder Equity may rise above about 136.4 M this year. From the period between 2010 and 2025, GlucoTrack, Other Stockholder Equity regression line of its data series had standard deviation of  47,911,570 and standard deviation of  47,911,570. View All Fundamentals
 
Other Stockholder Equity  
First Reported
2011-09-30
Previous Quarter
113.9 M
Current Value
118.3 M
Quarterly Volatility
42.3 M
 
Yuan Drop
 
Covid
Check GlucoTrack financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlucoTrack's main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.3 K, Interest Expense of 3.3 K or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 53.8 K, Dividend Yield of 0.0 or PTB Ratio of 32.09. GlucoTrack financial statements analysis is a perfect complement when working with GlucoTrack Valuation or Volatility modules.
  
Check out the analysis of GlucoTrack Correlation against competitors.
For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.

Latest GlucoTrack's Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of GlucoTrack over the last few years. It is GlucoTrack's Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GlucoTrack's overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

GlucoTrack Other Stockholder Equity Regression Statistics

Arithmetic Mean62,957,020
Geometric Mean43,119,179
Coefficient Of Variation76.10
Mean Deviation44,587,653
Median84,007,612
Standard Deviation47,911,570
Sample Variance2295.5T
Range122.9M
R-Value0.95
Mean Square Error236.6T
R-Squared0.90
Slope9,567,110
Total Sum of Squares34432.8T

GlucoTrack Other Stockholder Equity History

2025136.4 M
2024129.9 M
2023113 M
2022103.1 M
2021102.6 M
2020102.4 M
201989 M

About GlucoTrack Financial Statements

GlucoTrack investors utilize fundamental indicators, such as Other Stockholder Equity, to predict how GlucoTrack Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Other Stockholder Equity129.9 M136.4 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlucoTrack is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlucoTrack Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glucotrack Stock. Highlighted below are key reports to facilitate an investment decision about Glucotrack Stock:
Check out the analysis of GlucoTrack Correlation against competitors.
For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(58.20)
Return On Assets
(2.04)
Return On Equity
(19.43)
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.